Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) shares dropped 10.1% during trading on Monday. The company traded as low as $30.00 and last traded at $29.5510. 32,138 shares were traded during trading, a decline of 70% from the average daily volume of 108,111 shares. The stock had previously closed at $32.88.
Analysts Set New Price Targets
SGP has been the subject of several analyst reports. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Friday. Stifel Nicolaus raised their target price on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright raised their target price on shares of Spyglass Pharma from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday. Raymond James Financial assumed coverage on shares of Spyglass Pharma in a report on Friday, August 14th. They issued an “outperform” rating and a $39.00 price target on the stock. Finally, Citigroup raised their target price on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Spyglass Pharma currently has an average rating of “Moderate Buy” and an average price target of $45.83.
View Our Latest Stock Analysis on SGP
Spyglass Pharma Trading Down 8.2%
The company’s 50-day moving average is $28.78 and its 200 day moving average is $24.83. The firm has a market cap of $1.01 billion and a PE ratio of -3.94.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.07). On average, research analysts predict that Spyglass Pharma, Inc. will post -2.77 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in shares of Spyglass Pharma during the first quarter worth approximately $308,000. Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma in the 2nd quarter valued at $533,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the 1st quarter valued at about $726,000. Monashee Investment Management LLC acquired a new stake in Spyglass Pharma during the 1st quarter valued at $2,461,000. Finally, Affinity Asset Advisors LLC acquired a new position in Spyglass Pharma during the 1st quarter worth about $6,478,000.
About Spyglass Pharma
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
See Also
- Five stocks we like better than Spyglass Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
